Tumor testing, genomic testing, biomarker testing – these are all complicated names for the same thing. Regardless of how you refer to it, biomarker testing plays an important role in personalizing your cancer treatment, and advancements continue to be made as research into biomarker directed therapy continues.
We talked with several survivors about how biomarker testing impacted their treatment options and want to share their first-hand experiences with you, so you know you’re not alone.
Phuong Gallagher
KRAS, BRAF, HER2 NEGATIVE AND MSS/PMM
However, in a testament to the rapid pace of change in treatment options, she is now able to participate in an immunotherapy clinical trial, despite her KRAS mutation.
“Testing for biomarkers should not be “one and done.” Time and treatments can alter your biomarkers, so you will want to ensure that you have the most accurate information available when making major treatment decisions.”
Wenora Johnson
MSI-H, MSH2 MUTATION
Looking on the bright side, Wenora notes “…the positive side of MSI-H tumors is that they tend to have better prognosis and may respond to immune checkpoint inhibitors.” Wenora also notes that biomarker testing plays a critical role in her ongoing monitoring and risk management to ensure early detection of recurrences or other cancers associated with her Lynch syndrome.
“Biomarkers are powerful tools that may help doctors understand your cancer better and guide your treatment, but they don’t define you or your journey. While they may seem overwhelming at first, they’re here to give you more personalized, effective care and open up treatment options that are right for you.”
Amy Jensen
RAS wild type, RAF mutated, MSI stable, BRAF mutation D594G, APC and TP53 mutated
“Ask your doctor if they tested your biomarkers, and if they haven’t, ask if they can! Ask what your biomarkers mean to you. Even with what I know about biomarkers, it is still confusing!”
Tim McDonald
MSS, KRAS, BRAF, and NRAS wild types
Tim also eventually received a liver transplant during his course of treatment, and notes that “having MSS (microsatellite stable) made it more likely that he would be a strong candidate (for a transplant).”
How do you take the next step?
share your story
Thank you to our sponsors for supporting our biomarker education!